Atrium Therapeutics, Inc. Common Stock (RNA) is a publicly traded Healthcare sector company. As of November 12, 2026, RNA trades at $7.57 with a market cap of $136.16M and a P/E ratio of -1.61. RNA moved -5.78% today. Year to date, RNA is -89.59%; over the trailing twelve months it is -89.38%. Its 52-week range spans $7.49 to $73.06. Analyst consensus is strong buy with an average price target of $21.25. Rallies surfaces RNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
4 analysts cover RNA: 0 strong buy, 4 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $21.25.
| Metric | Value |
|---|---|
| Price | $7.57 |
| Market Cap | $136.16M |
| P/E Ratio | -1.61 |
| EPS | $-4.97 |
| Dividend Yield | 0.00% |
| 52-Week High | $73.06 |
| 52-Week Low | $7.49 |
| Volume | 273.17K |
| Avg Volume | 0 |
| Revenue (TTM) | $18.75M |
| Net Income | $-684.63M |
| Gross Margin | 0.00% |
4 analysts cover RNA: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $21.25.